text: Yo, listen up, I got some facts to share,
  'Bout EGFR mutation-positive NSCLC, yeah, that's rare.
  In the advanced setting, when it's time to treat,
  EGFR-TKIs, they can't be beat.
  
  First-line treatment, that's the way to go,
  For NSCLC patients with EGFRm in the know.
  And Osimertinib, a third-gen TKI,
  Got the green light in 2017, oh my!
  
  It's the second-line option, for all to see,
  Treats EGFR T790M-positive NSCLC, you see.
  Now let me break it down, here's the deal,
  The REFLECT study, it's the real-world appeal.
  
  It examines the patterns, the tests, and more,
  In patients with advanced NSCLC, that's for sure.
  They got treated with 1G or 2G TKIs,
  Before Osimertinib's first-line approval, oh my.
  
  So there you have it, the story's told,
  EGFR-TKIs, they're worth their weight in gold.
  The REFLECT study, shedding light,
  On the treatments and outcomes, shining bright.